Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
PCVXthis companyVaxcyte, Inc.	$65.17	-8.2×	2.34×	0×	-8.54×	-100.9%	0.0%	0.0%	0.0%	-28.5%	-32.5%	-10.7%	0.09×	-0.07×	0×	7.91×	0.0%	0	13.18	2	C
ARCTArcturus Therapeutics Holdings Inc.	$10.44	-2.55×	0.78×	2.5×	0.61×	-144.1%	95.5%	-111.5%	-97.9%	-30.7%	-31.4%	-44.2%	0.12×	3.28×	0×	6.64×	0.0%	1	-0.72	2	C
GOVXGeoVax Labs, Inc.	$0.16	-0.19×	1.07×	1.65×	-0.09×	3.5%	-628.0%	-869.3%	-862.3%	-561.2%	-463.5%	-524.2%	0.22×	0.1×	0×	2.74×	0.0%	2	-62.33	2	C+
IBRXImmunityBio, Inc.	$7.00	-5.21×	-3.65×	16.08×	-11.68×	-355.9%	99.3%	-226.0%	-310.2%	70.3%	-56.9%	-17.0%	-1.76×	-3.53×	-2.28×	5.1×	0.0%	3	-10.89	2	C
MRNAModerna, Inc.	$271.95	-4.06×	1.33×	5.9×	-4.23×	-100.7%	55.3%	-158.1%	-145.2%	-32.6%	-29.7%	-18.0%	0.22×	0.27×	-307.4×	3.29×	0.0%	2	12.95	1	C-
NVAXNovavax, Inc.	$10.64	2.47×	-8.52×	0.97×	2.23×	-870.5%	93.7%	50.1%	39.2%	-344.7%	78.0%	-23.0%	-1.95×	0.02×	24.98×	2.13×	0.0%	1	-5.75	2	B-
Peer median	—	-2.55×	0.78×	2.5×	-0.09×	-144.1%	93.7%	-158.1%	-145.2%	-32.6%	-31.4%	-23.0%	0.12×	0.1×	0×	3.29×	0.0%	2	-5.75	2	—